Not in my opinion. We initially relied on India for our saliva clinical trial, but because that was going to take too long, we moved it to the UK to accelerate it:
"We are in the process of preparing and sending test kits from Spain and readers to the UK to complete this saliva validation work, which we expect will be finalised and CE Mark approved by June this year."
So IMO, with or without India, it is not going to make a difference.
Ann: Quarterly Activities Report, page-34
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $51.83M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.2¢ | 2.1¢ | $8.816K | 408.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 1153507 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 299817 | 2 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| ADO (ASX) Chart |